As 2025 comes to a close, we’ve been spending time reflecting on the work, the conversations, and the people that shaped the year at Endpoint Preclinical. The past 12 months reinforced something we believe deeply: meaningful progress in preclinical research doesn’t come from one-off solutions, but from trusted collaboration and the right expertise applied at the right moment.

Throughout the year, we had the opportunity to support a wide range of scientific efforts across the preclinical landscape. From early problem-solving discussions to more complex, hands-on engagements, our focus remained consistent—bringing experienced, specialized expertise directly where it was needed, while keeping execution streamlined and focused on the science. Endpoint supported over 80 preclinical projects this year, each one different in scope, challenge, and objective, but all rooted in thoughtful scientific problem-solving.

2025 was also a year of steady growth and expansion for Endpoint. We welcomed 12 new experts to the network, broadening the range of experience and perspectives available to our partners. In parallel, we launched 4 new training programs and expanded organized services across areas including neuroscience, pathology, toxicology, and ophthalmology, reflecting the evolving needs we’re seeing in preclinical research.

An important milestone in 2025 was the launch of our strategic partnership with PRA to support on-site, production-level surgical services. This collaboration reflects a shared commitment to bringing experienced surgical expertise directly into existing research environments, allowing teams to scale complex surgical work without disrupting established workflows or compromising quality. By combining Endpoint’s infrastructure and operational strength with PRA’s specialized surgical expertise, the partnership was designed to support consistency, efficiency, and rigor at production scale.

Looking ahead to 2026, our focus will shift toward deeper engagement—supporting more complex work, expanding opportunities for collaboration within the Expert Network, and creating value-driven scientific content that highlights the expertise of our consultants and the insights of our partners.

As we close out the year, we want to extend our sincere thanks to the collaborators, partners, and experts who trusted Endpoint with their work in 2025. The science is complex, the pace is demanding, and the stakes are high—but the relationships behind the work make all the difference. We’re grateful for what we’ve built together and look forward to what’s ahead.

With appreciation,

Cole McLarty & Andy Henton
Co-Founders, Endpoint Preclinical